A phase Ib, multicenter, open-label study of the antibody-drug conjugate trastuzumab deruxtecan (DS-8201a) combination with nivolumab for advanced HER2-expressing breast or urothelial cancer

被引：0

作者：

Hurvitz, S. A. ^{[1
]}

Galsky, M. D. ^{[2
]}

Shahidi, J. ^{[3
]}

Zhang, G. ^{[4
]}

Raza, S. ^{[3
]}

Necchi, A. ^{[5
]}

机构：

[1] UCLA Med Ctr, Dept Med, Los Angeles, CA USA

[2] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA

[3] Daiichi Sankyo Inc, Clin Dev, Basking Ridge, NJ USA

[4] Daiichi Sankyo Inc, Biostat & Data Management, Basking Ridge, NJ USA

[5] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

370TiP

引用

页数：1

共 50 条

[31] Updated Results of Phase 1 Study of DS-8201a in HER2-Expressing or - Mutated Advanced Non-Small-Cell Lung Cancer [J].

Tsurutani, J. ;

Park, H. ;

Doi, T. ;

Modi, S. ;

Takahashi, S. ;

Nakagawa, K. ;

Krop, I. ;

Waqar, S. ;

Yoh, K. ;

Li, B. ;

Taira, S. ;

Jikoh, T. ;

Singh, J. ;

Sugihara, M. ;

Janne, P. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S324-S324

[32] Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985) [J].

Xu, Zhuyu ;

Guo, Dandan ;

Jiang, Zhongliang ;

Tong, Rongsheng ;

Jiang, Peidu ;

Bai, Lan ;

Chen, Lu ;

Zhu, Yuxuan ;

Guo, Chun ;

Shi, Jianyou ;

Yu, Dongke .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2019, 183

[33] Phase I study of A166, an antibody-drug conjugate in advanced HER2-expressing solid tumours [J].

Zhang, Jian ;

Liu, Rujiao ;

Gao, Shuiping ;

Li, Wenhua ;

Chen, Yang ;

Meng, Yanchun ;

Liu, Chang ;

Jin, Wenyue ;

Wu, Junyan ;

Wang, Ying ;

Hao, Yanrong ;

Yi, Shuli ;

Qing, Yan ;

Ge, Junyou ;

Hu, Xichun .

NPJ BREAST CANCER, 2023, 9 (01)

[34] A phase 3, multicenter, randomized, open-label trial of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04) [J].

Modi, Shanu ;

Ohtani, Shoichiro ;

Lee, Caleb ;

Wang, Yibin ;

Saxena, Kapil ;

Cameron, David A. .

CANCER RESEARCH, 2020, 80 (04)

[35] Preclinical evaluation of trastuzumab deruxtecan (T-DXd; DS-8201a), a HER2 antibody-drug conjugate, in pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC) [J].

Hingorani, Pooja ;

Zhang, Wendong ;

Kurmasheva, Raushan ;

Zhang, Zhongting ;

Wang, Yifei ;

Xu, Zhaohui ;

Roth, Michael ;

Gill, Jonathan ;

Harrison, Douglas ;

Erickson, Stephen ;

Kolb, Edward A. ;

Smith, Malcolm ;

Houghton, Peter ;

Gorlick, Richard .

CANCER RESEARCH, 2020, 80 (16)

[36] Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors [J].

Doi, Toshihiko ;

Iwata, Hiroji ;

Tsurutani, Junji ;

Takahashi, Shunji ;

Park, Haeseong ;

Redfern, Charles H. ;

Shitara, Kohei ;

Shimizu, Chikako ;

Taniguchi, Hiroya ;

Iwasa, Tsutomu ;

Taira, Shinichiro ;

Lockhart, Albert C. ;

Fisher, Jennifer M. ;

Jikoh, Takahiro ;

Fujisaki, Yoshihiko ;

Lee, Caleb C. ;

Yver, Antoine ;

Tamura, Kenji .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[37] Trastuzumab deruxtecan (DS-8201a), a HER2-Targeting Antibody-Drug Conjugate with Topoisomerase I Inhibitor Payload, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/neu Expression [J].

Mauricio, Dennis ;

Bellone, Stefania ;

Manavella, Diego ;

Harold, Justin ;

Buza, Natalia ;

Altwerger, Gary ;

Menderes, Gulden ;

Ratner, Elena ;

Huang, Gloria ;

Clark, Mitchell ;

Andikyan, Vaagn ;

Azodi, Masoud ;

Schwartz, Peter ;

Santin, Alessandro .

GYNECOLOGIC ONCOLOGY, 2022, 166 :S31-S32

[38] Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression [J].

Mauricio, Dennis ;

Bellone, Stefania ;

Mutlu, Levent ;

McNamara, Blair ;

Manavella, Diego D. ;

Demirkiran, Cem ;

Verzosa, Miguel Skyler Z. ;

Buza, Natalia ;

Hui, Pei ;

Hartwich, Tobias Max Philipp ;

Harold, Justin ;

Yang-Hartwich, Yang ;

Zipponi, Margherita ;

Altwerger, Gary ;

Ratner, Elena ;

Huang, Gloria S. ;

Clark, Mitchell ;

Andikyan, Vaagn ;

Azodi, Masoud ;

Schwartz, Peter E. ;

Santin, Alessandro D. .

GYNECOLOGIC ONCOLOGY, 2023, 170 :38-45

[39] Phase III study of [fam-] trastuzumab deruxtecan (DS-8201a) vs TDM1 for HER2-positive breast cancer [J].

Verma, S. ;

Shahidi, J. ;

Lee, C. ;

Wang, K. ;

Cortes, J. .

ANNALS OF ONCOLOGY, 2019, 30

[40] [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01) [J].

不详 .

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) :7-9

← 1 2 3 4 5 →